Novel Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls
Journal of Nuclear Medicine, ISSN: 2159-662X, Vol: 64, Issue: 3, Page: 368-371
2023
- 12Citations
- 13Captures
- 6Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations12
- Citation Indexes12
- 12
- CrossRef1
- Captures13
- Readers13
- 13
- Mentions6
- News Mentions6
- News6
Most Recent News
Novel PET Radiotracer Reduces False-Positive Tumors After COVID-19 Vaccination
18F-FDG PET/CT detects approximately 73% of tumor lesions, while 68Ga-FAPI finds approximately 94%. Novel imaging agent 68Ga-FAPI can reduce the number of false-positive positron emission
Article Description
In the setting of ongoing coronavirus disease 2019 vaccination, vaccine-related tracer uptake in locoregional lymph nodes has become a well-known issue in tumor staging by F-FDG PET/CT. Ga-fibroblast-activation protein inhibitor (FAPI) PET/CT is a new oncologic imaging tool that may overcome this limitation. Methods: We assessed postvaccine head-to-head and same-day F-FDG and Ga-FAPI-46 PET/CT findings in a series of 11 patients from a large, prospective imaging registry. All patients with documented tracer uptake in locoregional lymph nodes on PET/CT or PET/MRI, after vaccination within 6 wk, were eligible for investigation. Result: Significant visual lymph node uptake adjacent to the injection site was noted in 11 of 11 (100%) patients with F-FDG PET/CT, versus 0 of 11 (0%) with Ga-FAPI PET/CT. F-FDG detected 73% and Ga-FAPI PET/CT 94% of all tumor lesions. Conclusion: In this case-series study, Ga-FAPI showed its potential to avoid F-FDG PET/CT postvaccination pitfalls and presented superior tumor localization.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85149427637&origin=inward; http://dx.doi.org/10.2967/jnumed.122.264872; http://www.ncbi.nlm.nih.gov/pubmed/36396454; http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.122.264872; https://dx.doi.org/10.2967/jnumed.122.264872; https://jnm.snmjournals.org/content/64/3/368
Society of Nuclear Medicine
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know